Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
|
| gptkbp:administeredBy |
oral route
|
| gptkbp:alsoKnownAs |
gptkb:molnupiravir
|
| gptkbp:approvedBy |
gptkb:India
gptkb:Japan gptkb:United_Kingdom gptkb:United_States |
| gptkbp:ATCCode |
J05AX27
|
| gptkbp:CASNumber |
2349386-89-4
|
| gptkbp:chemicalFormula |
C13H19N3O7
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
gptkb:Emory_University
gptkb:Merck_&_Co. gptkb:Ridgeback_Biotherapeutics |
| gptkbp:eliminatedIn |
renal
|
| gptkbp:firstDescribed |
2019
|
| https://www.w3.org/2000/01/rdf-schema#label |
EIDD-2801
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
RNA polymerase inhibitor
|
| gptkbp:molecularWeight |
329.31 g/mol
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prodrugOf |
NHC (EIDD-1931)
|
| gptkbp:sideEffect |
nausea
diarrhea dizziness |
| gptkbp:target |
gptkb:COVID-19
gptkb:influenza_virus other RNA viruses |
| gptkbp:usedFor |
gptkb:COVID-19
|
| gptkbp:bfsParent |
gptkb:Ridgeback_Biotherapeutics
gptkb:Molnupiravir |
| gptkbp:bfsLayer |
6
|